Is It My Thyroid? The Evidence For and Against Combination Thyroid Hormone Therapy

Friday, May 13, 2022

11:00 AM – 12:00 PM

Location: Breakout Room 4-Aqua ABC (Level 3)

Speaker(s)

Antonio C. Bianco, MD, PhD
Professor of Medicine
University of Chicago
CHICAGO, Illinois, United States

Disclosure: Abbott/AbbVie (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Allergan (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Synthonic (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

PDF Slides

Moderator(s)

Alex Tessnow, MD
Associate Professor
University of Texas Southwestern Medical Center
Southlake, Texas, United States

Disclosure: Horizon (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Spectrix Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

Learning Objectives:

Interpret serum T3 and serum T4 levels on LT4-treated patients;
Assess thyroid hormone-dependent parameters in LT4-treated patients;
Apply current views of when/how LT3 could be used in the treatment of hypothyroidism.

Participants should be aware of the following financial/non-financial relationships:

Antonio C. Bianco, MD, PhD: Abbott/AbbVie (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Allergan (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Synthonic (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)

Alex Tessnow, MD: Horizon (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Spectrix Therapeutics (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)